Welcome to our dedicated page for Repligen SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Repligen Corporation (NASDAQ: RGEN), a global life sciences company focused on bioprocessing technologies and systems for manufacturing biological drugs. As a Nasdaq-listed issuer, Repligen submits a range of regulatory documents that give detailed insight into its financial performance, governance and material events.
Among the key filings available are Form 10-K annual reports and Form 10-Q quarterly reports, which typically include audited or reviewed financial statements, management’s discussion and analysis, and information on Repligen’s bioprocessing focus areas: Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. These filings expand on the themes highlighted in the company’s earnings press releases and non-GAAP reconciliations.
Repligen also files Form 8-K current reports to disclose material events. Recent examples include 8-K filings referencing the release of second and third quarter 2025 financial results, as well as an 8-K describing the appointment of a Chief Accounting Officer to enhance the company’s financial reporting infrastructure and Sarbanes–Oxley oversight. Such filings can provide timely context on leadership changes, compensation decisions and other corporate developments.
Investors may also review proxy statements and, where applicable, Form 4 insider transaction reports to understand equity-based compensation and share activity by directors and officers. Together, these documents form the regulatory record of Repligen’s operations as a public company.
On Stock Titan, Repligen’s filings are updated as they are released on EDGAR, with AI-powered summaries that highlight key points from lengthy reports. This helps readers quickly identify major financial trends, governance changes and disclosures related to Repligen’s role as a life sciences and bioprocessing technology company.
Repligen Corporation reporting person Olivier Loeillot, who is listed as both a Director and the Chief Executive Officer, recorded a sale of common stock on 10/02/2025. The filing shows 1,248 shares were disposed of at a price of $145.23 per share, with 42,939 shares remaining beneficially owned after the transaction. The reported sale represents shares withheld by the issuer to satisfy tax withholding obligations arising from the release of restricted stock units, not an open-market purchase or voluntary sale. The Form 4 was signed on 10/06/2025 by an attorney-in-fact on behalf of the reporting person.
Repligen Corp (RGEN) Chief Financial Officer Jason K. Garland reported a non-derivative disposition on 09/25/2025 involving 412 shares of Common Stock sold at a price of $121.68 per share. The filing shows 13,383 shares remained beneficially owned by the reporting person after the transaction. The form identifies the transaction as related to tax withholding: the 412 shares were withheld by the issuer to satisfy the reporting person's tax withholding obligations upon the release of restricted stock units.
Repligen Corp (RGEN) director Anthony Hunt exercised options and sold shares on 09/10/2025 under a documented plan. Mr. Hunt exercised a stock option to acquire 20,000 shares at an exercise price of $33.87, resulting in 20,000 newly acquired shares recorded in Table II. On the same date he sold multiple blocks of common stock under a 10(b)5-1 trading plan, with weighted-average sale prices reported at $116.34, $118.32, $119.64, $120.19, $121.42 and $122.23 for different tranches. After these transactions his direct beneficial ownership of common stock is reported as 100,743 shares and he beneficially owns 182,344 shares underlying options.
Repligen Corp (RGEN) filed a Form 144 reporting a proposed sale of 29,111 common shares through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $3,508,378.25 and approximately 56,257,618 shares outstanding. The filing shows 9,111 shares acquired via restricted stock vesting on 03/01/2022 as compensation, and 20,000 shares associated with options (options granted 03/01/2018) to be sold on 09/10/2025 for cash. The filer reports no sales in the past three months. The notice includes the filer’s attestation that they are not aware of any undisclosed material adverse information about the issuer.
T. Rowe Price Associates, Inc. filed an Amendment No. 6 to Schedule 13G reporting ownership of 3,429,547 shares of Repligen Corp common stock, representing 6.1% of the class. The filing shows T. Rowe Price has sole voting power over 3,170,704 shares and sole dispositive power over 3,429,435 shares. No shared voting or dispositive power is reported.
The filer certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing lists Maryland as the filer’s place of organization and provides issuer and filer addresses.
Repligen Corporation officer Violetta Hughes reported awards and option grants in a Form 4 filing. On 09/02/2025 she was awarded 4,142 restricted stock units, each representing a contingent right to one share; the RSUs vest in equal annual installments over five years beginning on the first anniversary of the grant and will be settled only in shares, so they are reported as 4,142 shares beneficially owned following the transaction. On the same date she acquired a stock option to buy 3,914 shares with an exercise price of $120.69 and an expiration date of 09/02/2035; those options also vest in equal annual instalments over five years. The Form 4 is signed by an attorney-in-fact and filed 09/04/2025.
Repligen Corp (RGEN) insider transaction summary. Olivier Loeillot, who serves as both Director and Chief Executive Officer, reported a transaction dated 09/03/2025 showing 2,506 shares of Repligen common stock were disposed of at a price of $116.18 per share. The filing explains these shares were withheld by the issuer to satisfy tax withholding obligations arising upon the release of restricted stock units. After the withholding, Loeillot beneficially owns 44,187 shares outright. The Form 4 was filed by one reporting person and signed on behalf of Loeillot by Jennifer Carmichael (Attorney in Fact) on 09/04/2025.
Violetta Hughes, identified as Chief Accounting Officer of Repligen Corporation (RGEN), filed an initial Form 3 reporting the event dated 09/01/2025. The filing states that no securities are beneficially owned by the reporting person. The form is signed by Violetta Hughes on 09/04/2025 and references an attached Power of Attorney (Exhibit 24.1). The document is an initial ownership disclosure and contains no entries in the non-derivative or derivative securities tables.
Repligen Corporation has appointed Violetta Hughes as Chief Accounting Officer, effective September 1, 2025, making her the company’s principal accounting officer. Chief Financial Officer Jason K. Garland will remain in his role, with more of his time directed toward corporate strategy, financial planning and analysis, capital markets and growth initiatives.
Hughes brings over 25 years of finance and accounting experience from prior chief accounting officer and controllership roles at Azenta, Akebia Therapeutics and AMAG Pharmaceuticals, with a background in financial governance and Sarbanes–Oxley compliance. Her compensation package includes a $395,000 annual base salary, a $150,000 signing bonus, an annual target bonus of up to 50% of base salary, and annual equity awards totaling $750,000 in restricted stock units and stock options that vest in equal installments over five years.
Repligen Corp director Martin D. Madaus, through the Martin D. Madaus 2011 Revocable Trust, bought 1,800 shares of Repligen common stock in an open-market purchase. The weighted average price was $112.128 per share, with trades ranging from $111.72 to $112.35. Following these transactions, Madaus directly holds 5,586 shares, the revocable trust holds 1,800 shares, and a spouse trust holds 11 shares.